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Invasive Penicillin-Resistant Pneumococcal Infections:
A Prevalence and Historical Cohort Study
More than 25 years ago, isolates of Streptococ-
cus pneumoniae were uniformly susceptible to
penicillin. However, since a penicillin-resistant
pneumococcus was first identified in 1967 (1), the
incidence of penicillin-resistant S. pneumoniae
(PRSP) strains has been gradually increasing. In
certain areas of the United States, PRSP strains
have become widespread; Alaska has the highest
reported prevalence, 26% (2); a recent study con-
ducted in Atlanta, Georgia, found a 25% preva-
lence of PRSP (3). Outside the United States, an
even higher (33%-58%) prevalence of PRSP has
been reported (2).
Pneumococcal infections are a leading cause of
morbidity and mortality in the United States. S.
pneumoniae causes more than 500,000 cases of
pneumonia,55,000 cases of bacteremia,and 6,000
cases of meningitis annually, which result in
40,000deaths(4).Thedeathratefrompneumococ-
cal bacteremia approaches 30%,despite the use of
appropriate antimicrobial therapy (5). Reports of
refractory illness due to resistant pneumococci
demonstrate the clinicalrelevance ofthesestrains
(6,7). Identifying risk factors in the development
of PRSP infections is important for both the pre-
vention and treatment of these infections.
T h ep r e v a l e n c eo fi n v a s i v ei n f e c t i o n sd u et o
PRSP was previously studied in Denver, Colorado
(8,9). We undertook the study described here to
d e t e r m i n et h ep r e v a l e n c eo fi n v a s i v eP R S Pi n f e c -
tions in the Colorado Front Range and to deter-
mine whether invasive PRSP infections have
increasedinmetropolitanDenversincetheearlier
studies.Inaddition,westudiedacohortofpatients
who had invasive pneumococcal disease during
1994 in metropolitan Denver to ascertain risk
factors for invasive PRSP infections.
Twenty-six hospital microbiology laboratories
in the Colorado Front Range,which comprises the
10 largest counties in Colorado and 80% of the
state’s population (10), submitted to the Colorado
Department of Public Health and Environment
reports of all blood and cerebrospinal fluid (CSF)
isolates of S. pneumoniae that were tested for
penicillin susceptibility during 1994. (Penicillin
susceptibility testing on invasive pneumococcal
isolates was standard practice for the laboratories
and did not depend on a clinician’s request.) For
the part of the study that assessed prevalence,
penicillin resistance was defined as a minimum
inhibitory concentration (MIC) of ³ 0.12 µg/ml or
an oxacillin zone of inhibition < 20 mm. Isolates
that were tested by an MIC method were further
classified as intermediately (0.12 µg/ml-1.0 µg/ml)
or highly (³ 2.0 µg/ml) penicillin resistant. For the
partofthestudyinwhichthecohortwasanalyzed,
only isolates that were confirmed as penicillin
resistant (i.e., MIC ³ 0.12 µg/ml) by either broth
dilution or the E test (AB Biodisk,North America,
Inc., Culver City, California) were included. Data
for the cohort study were collected by chart review
by the principal investigator, and telephone inter-
views of patients were conducted by trained inter-
viewers in the Health Statistics Survey Research
Unit of the Colorado Department of Public Health
and Environment. For patients under 18 years of
age, a parent or legal guardian was interviewed.
When patients had died, a relative of the patient
(if available) was interviewed.
Invasivepneumococcalinfectionswerefoundin
363 patients in the Colorado Front Range; 49
(13%) of the infections were resistant to penicillin.
In metropolitan Denver, 29 (14%) of the invasive
pneumococcal infections were penicillin-resistant,
of which 20 (69%) were intermediately penicillin-
resistant (i.e., MIC 0.12-1.0 µg/ml), and 9 (31%)
were highly penicillin-resistant (i.e., MIC ³ 2.0
µg/ml). This prevalence rate of invasive PRSP
infections is significantly higher than the pre-
viously reported rates in Denver of 1% (8) and 7%
(9). Previous surveillance of invasive PRSP iso-
lates showed that one region in the United States,
which included Colorado, had a significantly
higher rate of penicillin resistance among pneu-
mococcal isolates than other U.S. regions (11).
Half of the PRSP strains in the cohort part of
the study that were tested for cephalosporin sus-
ceptibilitywereresistanttoanextended-spectrum
cephalosporin. Our results are similar to the re-
cent Atlanta study which found that 34% to 54%
of PRSP infections were resistant to an extended-
spectrum cephalosporin (3).These rates are much
higher than other reported rates of cephalosporin
resistance among PRSP isolates of 27% in Ken-
tucky and 25% in Tennessee,(12).This has impor-
tant implications for the management of invasive
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MICs of ß-lactam antibiotics in the cerebrospinal
fluid may be less than the MICs of ß-lactam anti-
biotics in the blood (13). The Centers for Disease
Control and Prevention recommends thatinareas
where pneumococcal resistance to cephalosporins
is high, empiric therapy with vancomycin plus an
extended-spectrum cephalosporin should be con-
sidered in all cases of meningitis potentially
caused by S. pneumoniae, until the results of cul-
ture and susceptibility testing are available (14).
Anumberofstudieshaveaddressedtheclinical
r e l e v a n c eo fP R S Pi n f e c t i o n sa n dh a v ea t t e m p t e d
to identify predictive factors for the development
of these infections. In our analysis of the demo-
graphic and clinical characteristics of the study
population (Table), we found that day-care atten-
d a n c eb yam e m b e ro ft h ep a t i e n t ’ sh o u s e h o l di n
the 3 months before the patient’s illness was asso-
ciated with invasive PRSP infections.Indeed,26%
of patients with PRSP infections, compared with
7% of patients with penicillin-sensitive infections,
hadat leastone memberin
their household, excluding
the patient, who had been
attending a day-care cen-
ter before becoming ill.
This study is unique in
th at,toourknowledge ,da y-
care attendance among
household members of pa-
tients has not been studied.
Even though most studies
have not specifically con-
sidered family members as
a potential mode of PRSP
transmission, rates of na-
sopharyngeal carriage of
PRSP are significantly
higherinfamilycontactsof
children colonized with
PRSP who were attending
day-care centers (7, 15).
Our finding that pa-
tients with PRSP infec-
tions were more likely to
have had a child in their
household who had at-
tended day-careduringthe
months before their illness
suggests that day-care set-
tings may serve as foci for
spreading resistant pneu-
mococcal strains. Antibiot-
ics are extensively used to
treat upper respiratory in-
fections that children at-
tending day-care centers
often have; the practice of
administering a prolonged
courseofprophylacticanti-
biotics to children with
recurrent otitis media who
Table.Demographic and clinical characteristics of patients with invasive penicillin-resistant
S.pneumoniae (PRSP) and penicillin-sensitive S.pneumoniae (PSSP) infections
PRSP; PSSP; Odds ratio
n = 29 (%) n = 180 (%) (95% confidence
interval)
Demographic characteristics
Age, years
< 5 11 (38) 39 (22) 1.9 (0.4-9.1)
5-64 8 (28) 93 (52) Reference
> 64 10 (34) 48 (27) 1.9 (0.5-7.1)
Sex
Male 12 (41) 104 (58) Reference
Female 17 (59) 76 (42) 1.8 (0.6-5.4)
Race
a
White 16 (55) 100 (56) Reference
Nonwhite 11 (38) 68 (38) 1.4 (0.5-3.9)
Clinical characteristics
Site of infection
Blood 26 (90) 171 (95) Reference
CSF 3 (10) 9 (5) 0.8 (0.1-5.1)
Underlying medical 14 (48) 108 (60) 1.0 (0.3-3.2)
condition
Antibiotic use
b 14 (52) 56 (39) 2.5 (0.9-7.1)
No history of 26 (90) 163 (91) 0.7 (0.1-3.4)
penicillin allergy
c
Previous hospitalization
d 5 (19) 33 (23) 0.3 (0.1-1.5)
Day-care attendance
Patients < 11 years
e 5 (50) 19 (50) 1.1 (0.4-2.7)
Household member(s)
f 7 (26) 10 (7) 8.1 (2.2-30.7)
Residence in a long-term
care facility
(patients > 64 years)
g 2 (20) 13 (27) 0.7 (0.1-3.6)
Hospital-acquired 1 (3) 8 (4) 0.4 (0.04-4.9)
infection
Outcome
Survived 25 (86) 156 (87) Reference
Died 4 (14) 24 (13) 1.6 (0.4-6.3)
a Missing information on 2 PRSP and 12 PSSP patients.
b Includes patients who had taken an antibiotic in the 3 months before illness; missing information on 2 PRSP and 36
PSSP patients.
c Missing information on 1 PSSP patient.
d Patients who were hospitalized in the 3 months before illness;missing information on 2 PRSP and 34 PSSP patients.
e Children < 11 years of age who attended day care in the 3 months before illness; children < 11 years of age, N = 56
(PRSP = 12, PSSP = 44);missing information on 2 PRSP and 6 PSSP patients.
f Patients with at least 1 child < 11 years of age (excluding the patient) in the household who attended day care in the 3
months before illness;missing information on 2 PRSP and 39 PSSP patients.
g Adults > 64 years of age who resided in a LTC facility in the 3 months before illness;adults > 64 years of age, N = 58
(PRSP = 10, PSSP = 48).
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lection of resistant bacteria in these settings (6,
15). These children may subsequently transmit
resistant S. pneumoniae to susceptible persons in
their households. Thus, patterns of antibiotic
treatment of children who attendday-care centers
mayexplainwhyday-careattendancemightfacili-
tate PRSP transmission. The likelihood that day-
care settings may serve as reservoirs for
antibiotic-resistant pneumococci indicates that
the efficacy of prophylactic antibiotics for otitis
media should be reassessed, especially when
PRSP is present in a community.
Furthermore, carriage of or infection with
PRSP has been associated with recent use of anti-
biotics (17). Our study showed that patients with
PRSPinfectionsweremorelikelytohavetakenan
antibiotic in the 3 months before theirillnessthan
patients with penicillin-sensitive pneumococcal
infections. This finding supports the theory that
antibiotic resistance has developed because of the
widespread availability and use of antibiotics.
Since the beginning of the antibiotic era 50 years
ago, it has been well recognized that antibiotics
ha vebeena ndcontinuetob einappropriatelyused
(18).
Theemergenceofdrug-resistantS.pneumoniae
emphasizestheimportanceoffollowingtherecom-
mendation of the Immunization Practices Advi-
soryCommittee thatallpersons2yearsofageand
older who are at high risk for pneumococcal dis-
ease receive the 23-valent pneumococcal capsular
polysaccharide vaccine. Because of its lack of im-
munogenicity and efficacy, the pneumococcal vac-
cine has not been licensed for children under 2
years of age (14). The high prevalence of PRSP
amongyoungchildren(3,17),andthepotentialfor
these children to transmit PRSP to susceptible
persons,underscoretheneedforaneffectivepneu-
mococcal vaccine for this age group.
Antimicrobial resistance contributes to in-
creased morbidity,mortality,and health care costs
(19). The solution lies in changing antibiotic pre-
scribing patterns, changing patient attitudes
about the necessity of antibiotics, increasing sur-
veillance of drug-resistant organisms, improving
techniques for antibiotic susceptibility testing,
and investing in research and development of
newer antimicrobial agents.
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